Iodine

Summary

Iodine (CHEMBL1201225) is an approved small molecule (ATC D08AG03); indicated across 6 conditions including thyroid tumor and heart failure.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D08AG03
• Indications: 6 conditions
• Clinical trials: 50
• Chemistry: 253.8089 Da · I2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1201225
Name	Iodine
Type	Small molecule
Max phase	3
FDA approved	yes
PubChem CID	807
ChEBI	CHEBI:17606
ATC	D08AG03
Molecular formula	I2
Molecular weight	253.8089
InChIKey	PNDPGZBMCMUPRI-UHFFFAOYSA-N

SMILES: II

IUPAC name: molecular iodine

ChEBI definition: Molecule comprising two covalently bonded iodine atoms with overall zero charge..

Pharmacological roles (ChEBI): nutrient.

Also known as: Iodine, Iodine mild, Iodine strong, Iodium, Iodum, Jodosan, NSC-42355, Tegodyne, iodine, SID144211611, IODINE

Patent coverage: 465,750 distinct patent families (1,175,299 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 1,174,981 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
thyroid tumor	3	MONDO:0015074	EFO:0003841
heart failure	2	MONDO:0005252	EFO:0003144
breast neoplasm	2	MONDO:0021100	MONDO:0007254
severe acute respiratory syndrome	1	MONDO:0005091	MONDO:0100096

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 50.

Phase distribution

Phase	Trials
Not specified	24
PHASE2	10
PHASE3	9
PHASE4	5
PHASE2/PHASE3	1
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01919593	PHASE4	COMPLETED	Efficacy of 2% Chlorhexidine Gluconate in 70% Alcohol Compare 10% Povidone Iodine in Blood Culture in Children
NCT02018094	PHASE4	COMPLETED	The Amputation Surgical Site Infection Trial (ASSIT)
NCT02462044	PHASE4	COMPLETED	Contrast Enhancement on Coronary Computed Tomographic Angiography
NCT03412734	PHASE4	TERMINATED	Vaginal Preparation Prior to Hysterectomy
NCT05512715	PHASE4	COMPLETED	LIthium as Bridging thErapy Prior to Radioactiveiodine in hyperThYroidism
NCT00079417	PHASE3	COMPLETED	Neoadjuvant Carboplatin and Vincristine and Standard Local Ophthalmic Therapy in Treating Patients With Intraocular Retinoblastoma
NCT00115895	PHASE3	UNKNOWN	The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy
NCT00175396	PHASE3	UNKNOWN	Androgen Suppression Combined With Elective Nodal and Dose Escalated Radiation Therapy
NCT01021007	PHASE3	COMPLETED	Clinical Research Study Efficacy of a Prototype Oral Rinse
NCT01174017	PHASE3	COMPLETED	Ability of a New Design of Iodine 125 Seed to Maintain Intended Position When Implanted in the Prostate
NCT01204359	PHASE3	UNKNOWN	The Prospective Study of Standard Treatment of Graves Disease Iodine 131 and Prevention of Adverse Reactions
NCT01717729	PHASE3	COMPLETED	Hepatocellular Carcinoma Treated With Iodine-125 Implantation
NCT03062605	PHASE3	COMPLETED	Reducing Bacteria That Cause Tooth Decay
NCT05142904	PHASE3	TERMINATED	Radiofrequency Ablation Versus I-131 for Solitary Autonomous Thyroid Nodules
NCT06220344	PHASE2/PHASE3	COMPLETED	Honey Dressing - A Preventive Procedure for Post-Surgical Site Infection.
NCT02152995	PHASE2	ACTIVE_NOT_RECRUITING	Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer
NCT06440850	PHASE2	RECRUITING	Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation
NCT00717587	PHASE2	UNKNOWN	Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer
NCT01444209	PHASE2	TERMINATED	Radioactive Iodine Implants for Pan-invasive Pituitary Macroadenomas
NCT01868035	PHASE2	COMPLETED	Iodine-131 Anti-B1 Antibody Consolidation for Patients With Non-Hodgkin’s Lymphoma Following First-line CHOP
NCT02393690	PHASE2	COMPLETED	Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer
NCT03109847	PHASE2	TERMINATED	Metformin to Mitigate Sequelae of Radioactive Iodine Treatment for Thyroid Cancers
NCT03688958	PHASE2	UNKNOWN	Iodine Supplementation on Breast Cancer
NCT04344236	PHASE2	WITHDRAWN	Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19
NCT04447183	PHASE2	UNKNOWN	The Safety and Effectiveness of rhTSH in Radioiodine Treatment for Patients With Differentiated Thyroid Cancer.
NCT04473261	PHASE1/PHASE2	UNKNOWN	Efficacy of Iodine Complex Against COVID-19 Patients
NCT02378246	Not specified	ACTIVE_NOT_RECRUITING	Swedish Iodine in Pregnancy and Development in Children (SWIDDICH) Study
NCT04288531	Not specified	ACTIVE_NOT_RECRUITING	Iodine Impact on Thyroid Function and Psychomotor Development, Observational Study in the Portuguese Minho Region
NCT04871139	Not specified	ACTIVE_NOT_RECRUITING	An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast Cancer
NCT06623500	Not specified	RECRUITING	Iodine Nutrition Status and Clinical Characteristics of Thyroid Cancer
NCT06626581	Not specified	NOT_YET_RECRUITING	Iodine Status and Characteristics of Papillary Thyroid Cancer
NCT06721273	Not specified	NOT_YET_RECRUITING	Iodine Supplementation and Fertility Parameters
NCT00509483	Not specified	COMPLETED	Three-Year Follow-up of Radioiodine Therapy for Goitre
NCT00791466	Not specified	COMPLETED	Maternal Iodine Supplementation and Effects on Thyroid Function and Child Development
NCT01216761	Not specified	COMPLETED	A Cluster-randomized Cross-over Trial Evaluating the Comparative Effectiveness of Three Skin Antiseptic Interventions
NCT01233050	Not specified	COMPLETED	Efficacy Comparison of Two Preoperative Skin Antisepsis Preparations in Colorectal Surgery
NCT01870583	Not specified	COMPLETED	Comparison of Surgical Skin Preps During Cesarean Deliveries
NCT01985204	Not specified	COMPLETED	Iodine Supplementation in Obesity
NCT02378233	Not specified	TERMINATED	Iodine Status in Swedish Lactating Women - Effect of Iodine Supplementation in the Thyroid Function of Mother and Infant
NCT02927119	Not specified	COMPLETED	Serum Thyroglobulin as a Marker of Iodine Status During Pregnancy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).